BioLineRx Ltd (BLRX) - Total Liabilities
Based on the latest financial reports, BioLineRx Ltd (BLRX) has total liabilities worth $16.86 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BioLineRx Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
BioLineRx Ltd - Total Liabilities Trend (2008–2025)
This chart illustrates how BioLineRx Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see BLRX current and non-current assets.
BioLineRx Ltd Competitors by Total Liabilities
The table below lists competitors of BioLineRx Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Regentis Biomaterials Ltd.
NYSE:RGNT
|
USA | $2.87 Million |
|
Clean Energy Technologies, Inc. Common Stock
NASDAQ:CETY
|
USA | $7.95 Million |
|
Gold Springs Resource Corp
TO:GRC
|
Canada | CA$3.44 Million |
|
Caring Brands, Inc. Common Stock
NASDAQ:CABR
|
USA | $384.47K |
|
Investcorp Credit Management BDC Inc
NASDAQ:ICMB
|
USA | $111.86 Million |
|
Sidomulyo Selaras Tbk
JK:SDMU
|
Indonesia | Rp116.09 Billion |
|
City Chic Collective Ltd
AU:CCX
|
Australia | AU$68.62 Million |
|
Oylum Sinai Yatirimlar AS
IS:OYLUM
|
Turkey | TL114.25 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down BioLineRx Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See BioLineRx Ltd (BLRX) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioLineRx Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioLineRx Ltd (2008–2025)
The table below shows the annual total liabilities of BioLineRx Ltd from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $17.56 Million | -30.99% |
| 2024-12-31 | $25.45 Million | -49.81% |
| 2023-12-31 | $50.70 Million | +98.50% |
| 2022-12-31 | $25.54 Million | +91.99% |
| 2021-12-31 | $13.30 Million | -47.33% |
| 2020-12-31 | $25.26 Million | +25.13% |
| 2019-12-31 | $20.19 Million | +35.37% |
| 2018-12-31 | $14.91 Million | +84.46% |
| 2017-12-31 | $8.08 Million | +106.65% |
| 2016-12-31 | $3.91 Million | +5.96% |
| 2015-12-31 | $3.69 Million | -16.09% |
| 2014-12-31 | $4.40 Million | -46.76% |
| 2013-12-31 | $8.27 Million | -11.47% |
| 2012-12-31 | $9.34 Million | +37.18% |
| 2011-12-31 | $6.81 Million | +6.40% |
| 2010-12-31 | $6.40 Million | -41.23% |
| 2009-12-31 | $10.88 Million | +10.09% |
| 2008-12-31 | $9.89 Million | -- |
About BioLineRx Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the tr… Read more